Thank you very much;
you're only a step away from
downloading your reports.
Todd Harrison: Biotech Is a Focus on Turnaround Tuesday
You can learn a lot just by watching.
Todd Harrison    

Editor's Note: Todd posts his vibes in real time each day on our Buzz & Banter where subscribers can follow over 30 professional traders as they share their ideas in real time. Want access to the Buzz plus unlimited market commentary? Click here to learn more about MVPRO.

 Signs, signs, everywhere there's signs.
-- Tesla 

Select sectors of the marketplace -- biotech and high-beta tech -- took it on the chin yesterday, and mainstay averages lost ground in the process. 

While technical damage was done -- NDX (INDEXNASDAQ:NDX) 3640 and RUT (INDEXRUSSELL:RUT) 1182 were notable casualties -- the bulls will argue it was healthy sector rotation out of overbought highfliers and into previous laggards and financial shares (which remain above BKX (INDEXSP:.BKX) 71.50).

When the dust settled, the S&P (INDEXSP:.INX) again tested the all-important 1850 level (for the sixth time, by my pen) and held, empowering traders to buy the dip anew. 

That sets the stage for Turnaround Tuesday, and not to disappoint, the early morning futures have followed the overseas bourses to the upside.  We should also note that the German DAX (INDEXDB:DAX) put some distance between current levels and the rip cord that is DAX 9K

The close -- stateside and abroad -- is more important than the opening, and we've seen several sessions of higher opens and heavy closes, so the technical context will remain fluid; and of course, with quarter-end five days away, we should respect the potential for the unexpected as unforeseen agendas play through.

The sector that has been in focus of late is biotech, for obvious reasons. This complex lead the tape higher the last five years -- trough to peak, the iShares Nasdaq Biotechnology Index ETF (NASDAQ:IBB) was up 368% since March 2009 vs. 180% for the S&P -- and since late February, the IBB lost 15% (the S&P is flat over the same period). Entering February, we asked the question, "Is the biotech bubble about to pop?" and that remains to be seen; thus far, it's merely deflated a bit while holding the lion's share of its outsized gains.

The answer to that question -- whether biotech is the early innings of a downdraft or a healthy rotation into fresh exposure -- is the trillion-dollar question for investors. It's been a long time since we've tossed the words "orderly unwind" around, which I suppose isn't a shocker given the proximity to fresh all-time highs. 

The good news for investors is that we don't have to answer that question right here, right now; we can stair-step our exposure, much like we did when we first flagged the break of IBB 260, and let the tape show us the way. The price action in the complex, however, should remain on your radar whether or not you're currently involved.

Random Thoughts:

  • Josh "The Reformed Broker" Brown shares his vibes on the state of biotech.
     
  • Into the downdraft yesterday, I bought back some GW Pharmaceuticals (NASDAQ:GWPH) under $62, in real time on our Buzz & Banter, as it tested the 50-day ($61.60) for the first time since last year. This has been one of the better cannabis plays, and it trades with biotech.
  • Speaking of cannabis opportunities, I updated my thoughts on the space yesterday, including where I sense we are in the longer-term cycle.
     
  • Another reason why S&P 1850 is so important? Check the cup-and-handle below.
  • JPMorgan (NYSE:JPM) acted great yesterday in the face of supply. That spells "real buyers" to these old eyes.
     
  • Gold $1,300 is double secret support (50-day and 200-day moving averages).
  • Is now the time to buy China and short US against it? Don't know, but that pairs trade has been ricocheting around my mind.
     
  • A little gratitude goes a long way -- now more than ever. As always, I hope this finds you well
R.P.

Twitter: @todd_harrison

Follow Todd and over 30 professional traders as they share their ideas in real-time with a FREE 14 day trial to Buzz & Banter.
< Previous
  • 1
Next >
Position in GWPH.

Todd Harrison is the founder and Chief Executive Officer of Minyanville. Prior to his current role, Mr. Harrison was President and head trader at a $400 million dollar New York-based hedge fund. Todd welcomes your comments and/or feedback at todd@minyanville.com.

The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.

Todd Harrison: Biotech Is a Focus on Turnaround Tuesday
You can learn a lot just by watching.
Todd Harrison    

Editor's Note: Todd posts his vibes in real time each day on our Buzz & Banter where subscribers can follow over 30 professional traders as they share their ideas in real time. Want access to the Buzz plus unlimited market commentary? Click here to learn more about MVPRO.

 Signs, signs, everywhere there's signs.
-- Tesla 

Select sectors of the marketplace -- biotech and high-beta tech -- took it on the chin yesterday, and mainstay averages lost ground in the process. 

While technical damage was done -- NDX (INDEXNASDAQ:NDX) 3640 and RUT (INDEXRUSSELL:RUT) 1182 were notable casualties -- the bulls will argue it was healthy sector rotation out of overbought highfliers and into previous laggards and financial shares (which remain above BKX (INDEXSP:.BKX) 71.50).

When the dust settled, the S&P (INDEXSP:.INX) again tested the all-important 1850 level (for the sixth time, by my pen) and held, empowering traders to buy the dip anew. 

That sets the stage for Turnaround Tuesday, and not to disappoint, the early morning futures have followed the overseas bourses to the upside.  We should also note that the German DAX (INDEXDB:DAX) put some distance between current levels and the rip cord that is DAX 9K

The close -- stateside and abroad -- is more important than the opening, and we've seen several sessions of higher opens and heavy closes, so the technical context will remain fluid; and of course, with quarter-end five days away, we should respect the potential for the unexpected as unforeseen agendas play through.

The sector that has been in focus of late is biotech, for obvious reasons. This complex lead the tape higher the last five years -- trough to peak, the iShares Nasdaq Biotechnology Index ETF (NASDAQ:IBB) was up 368% since March 2009 vs. 180% for the S&P -- and since late February, the IBB lost 15% (the S&P is flat over the same period). Entering February, we asked the question, "Is the biotech bubble about to pop?" and that remains to be seen; thus far, it's merely deflated a bit while holding the lion's share of its outsized gains.

The answer to that question -- whether biotech is the early innings of a downdraft or a healthy rotation into fresh exposure -- is the trillion-dollar question for investors. It's been a long time since we've tossed the words "orderly unwind" around, which I suppose isn't a shocker given the proximity to fresh all-time highs. 

The good news for investors is that we don't have to answer that question right here, right now; we can stair-step our exposure, much like we did when we first flagged the break of IBB 260, and let the tape show us the way. The price action in the complex, however, should remain on your radar whether or not you're currently involved.

Random Thoughts:

  • Josh "The Reformed Broker" Brown shares his vibes on the state of biotech.
     
  • Into the downdraft yesterday, I bought back some GW Pharmaceuticals (NASDAQ:GWPH) under $62, in real time on our Buzz & Banter, as it tested the 50-day ($61.60) for the first time since last year. This has been one of the better cannabis plays, and it trades with biotech.
  • Speaking of cannabis opportunities, I updated my thoughts on the space yesterday, including where I sense we are in the longer-term cycle.
     
  • Another reason why S&P 1850 is so important? Check the cup-and-handle below.
  • JPMorgan (NYSE:JPM) acted great yesterday in the face of supply. That spells "real buyers" to these old eyes.
     
  • Gold $1,300 is double secret support (50-day and 200-day moving averages).
  • Is now the time to buy China and short US against it? Don't know, but that pairs trade has been ricocheting around my mind.
     
  • A little gratitude goes a long way -- now more than ever. As always, I hope this finds you well
R.P.

Twitter: @todd_harrison

Follow Todd and over 30 professional traders as they share their ideas in real-time with a FREE 14 day trial to Buzz & Banter.
< Previous
  • 1
Next >
Position in GWPH.

Todd Harrison is the founder and Chief Executive Officer of Minyanville. Prior to his current role, Mr. Harrison was President and head trader at a $400 million dollar New York-based hedge fund. Todd welcomes your comments and/or feedback at todd@minyanville.com.

The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.

More From Todd Harrison
Daily Recap
Todd Harrison: Biotech Is a Focus on Turnaround Tuesday
You can learn a lot just by watching.
Todd Harrison    

Editor's Note: Todd posts his vibes in real time each day on our Buzz & Banter where subscribers can follow over 30 professional traders as they share their ideas in real time. Want access to the Buzz plus unlimited market commentary? Click here to learn more about MVPRO.

 Signs, signs, everywhere there's signs.
-- Tesla 

Select sectors of the marketplace -- biotech and high-beta tech -- took it on the chin yesterday, and mainstay averages lost ground in the process. 

While technical damage was done -- NDX (INDEXNASDAQ:NDX) 3640 and RUT (INDEXRUSSELL:RUT) 1182 were notable casualties -- the bulls will argue it was healthy sector rotation out of overbought highfliers and into previous laggards and financial shares (which remain above BKX (INDEXSP:.BKX) 71.50).

When the dust settled, the S&P (INDEXSP:.INX) again tested the all-important 1850 level (for the sixth time, by my pen) and held, empowering traders to buy the dip anew. 

That sets the stage for Turnaround Tuesday, and not to disappoint, the early morning futures have followed the overseas bourses to the upside.  We should also note that the German DAX (INDEXDB:DAX) put some distance between current levels and the rip cord that is DAX 9K

The close -- stateside and abroad -- is more important than the opening, and we've seen several sessions of higher opens and heavy closes, so the technical context will remain fluid; and of course, with quarter-end five days away, we should respect the potential for the unexpected as unforeseen agendas play through.

The sector that has been in focus of late is biotech, for obvious reasons. This complex lead the tape higher the last five years -- trough to peak, the iShares Nasdaq Biotechnology Index ETF (NASDAQ:IBB) was up 368% since March 2009 vs. 180% for the S&P -- and since late February, the IBB lost 15% (the S&P is flat over the same period). Entering February, we asked the question, "Is the biotech bubble about to pop?" and that remains to be seen; thus far, it's merely deflated a bit while holding the lion's share of its outsized gains.

The answer to that question -- whether biotech is the early innings of a downdraft or a healthy rotation into fresh exposure -- is the trillion-dollar question for investors. It's been a long time since we've tossed the words "orderly unwind" around, which I suppose isn't a shocker given the proximity to fresh all-time highs. 

The good news for investors is that we don't have to answer that question right here, right now; we can stair-step our exposure, much like we did when we first flagged the break of IBB 260, and let the tape show us the way. The price action in the complex, however, should remain on your radar whether or not you're currently involved.

Random Thoughts:

  • Josh "The Reformed Broker" Brown shares his vibes on the state of biotech.
     
  • Into the downdraft yesterday, I bought back some GW Pharmaceuticals (NASDAQ:GWPH) under $62, in real time on our Buzz & Banter, as it tested the 50-day ($61.60) for the first time since last year. This has been one of the better cannabis plays, and it trades with biotech.
  • Speaking of cannabis opportunities, I updated my thoughts on the space yesterday, including where I sense we are in the longer-term cycle.
     
  • Another reason why S&P 1850 is so important? Check the cup-and-handle below.
  • JPMorgan (NYSE:JPM) acted great yesterday in the face of supply. That spells "real buyers" to these old eyes.
     
  • Gold $1,300 is double secret support (50-day and 200-day moving averages).
  • Is now the time to buy China and short US against it? Don't know, but that pairs trade has been ricocheting around my mind.
     
  • A little gratitude goes a long way -- now more than ever. As always, I hope this finds you well
R.P.

Twitter: @todd_harrison

Follow Todd and over 30 professional traders as they share their ideas in real-time with a FREE 14 day trial to Buzz & Banter.
< Previous
  • 1
Next >
Position in GWPH.

Todd Harrison is the founder and Chief Executive Officer of Minyanville. Prior to his current role, Mr. Harrison was President and head trader at a $400 million dollar New York-based hedge fund. Todd welcomes your comments and/or feedback at todd@minyanville.com.

The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.

EDITOR'S PICKS
 
WHAT'S POPULAR